The Liver Meeting 2021 (American Association for the Study of Liver Diseases)
Kowdley et al • 2021 •
© 2024 Corcept Therapeutics, Incorporated
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
Pivonello et al • 2021 • Front. Endocrinol., 14 July 2021
Relacorilant With Nab-paclitaxel: Safety and Activity in Patients With Pancreatic Ductal Adenocarcinoma and Ovarian Cancer
Munster et al. • 2019 •
Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients With Endogenous Hypercortisolism
Pivonello et al. • 2019 • American Association of Clinical Endocrinologists (AACE) 28th Annual Scientific & Clinical Congress
Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice
Koorneef et al. • 2018 • Endocrinology. 2018, 159(12):3925–3936